Literature DB >> 11136291

Immunotherapy for renal carcinoma: theoretical basis and current standard of care.

P A Vasey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11136291      PMCID： PMC2015010          DOI： 10.1046/j.1365-2125.2000.00300.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  41 in total

1.  Irreversible inactivation of interleukin 2 in a pump-based delivery environment.

Authors:  S T Tzannis; W J Hrushesky; P A Wood; T M Przybycien
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

3.  Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

Authors:  M E Gleave; M Elhilali; Y Fradet; I Davis; P Venner; F Saad; L H Klotz; M J Moore; V Paton; A Bajamonde
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

4.  Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience.

Authors:  E Huland; H Heinzer; T S Mir; H Huland
Journal:  Cancer J Sci Am       Date:  1997-12

5.  An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.

Authors:  J C Yang; S A Rosenberg
Journal:  Cancer J Sci Am       Date:  1997-12

6.  High-dose aldesleukin in renal cell carcinoma: long-term survival update.

Authors:  R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; G Fyfe
Journal:  Cancer J Sci Am       Date:  1997-12

Review 7.  Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

Authors:  J P Dutcher; M Atkins; R Fisher; G Weiss; K Margolin; F Aronson; J Sosman; M Lotze; M Gordon; T Logan; J Mier
Journal:  Cancer J Sci Am       Date:  1997-12

8.  The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy.

Authors:  M T Lotze; B Hellerstedt; L Stolinski; T Tueting; C Wilson; D Kinzler; H Vu; J T Rubin; W Storkus; H Tahara; E Elder; T Whiteside
Journal:  Cancer J Sci Am       Date:  1997-12

9.  Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.

Authors:  P J Gold; J A Thompson; D R Markowitz; S Neumann; A Fefer
Journal:  Cancer J Sci Am       Date:  1997-12

10.  Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.

Authors:  E Lopez Hänninen; H Kirchner; J Atzpodien
Journal:  J Urol       Date:  1996-01       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.